{"id":5392,"date":"2026-02-20T11:26:56","date_gmt":"2026-02-20T09:26:56","guid":{"rendered":"https:\/\/cvja.co.za\/journal\/?p=5392"},"modified":"2026-02-20T11:26:56","modified_gmt":"2026-02-20T09:26:56","slug":"cvja-2025-107","status":"publish","type":"post","link":"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/","title":{"rendered":"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs"},"content":{"rendered":"
\r\n
\r\n
\r\n \r\n \r\nKahraman Cosansu, Sabiye Yilmaz, Cagin Mustafa Ureyen, Mustafa Gokhan Vural\r\n<\/div> \r\n<\/div> \r\n
\r\n Copyright:<\/strong> Clinics Cardive Publishing (Pty) Ltd. publisher\r\n of Cardiovascular Journal of Africa.<\/div>\r\n
<\/div> \r\n
\r\n
\r\n Abstract \r\n <\/div> \r\n \r\n
\r\n \r\n \r\n \r\n \r\n\r\n Background:<\/strong> \r\n \r\nThe systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.\r\n
\r\n\r\n Methods:<\/strong> \r\n \r\nA total of 467 patients with NVAF treated with DOACs from 2018 to 2021 were retrospectively enrolled in this cohort study. Demographics, medication, and outcome data were collected for each patient. SII was calculated from complete blood counts as the ratio of neutrophil-to-lymphocyte count multiplied by the platelet count. The primary outcome was major adverse events (MAEs), which include major bleeding, stroke, and death.\r\n
\r\n \r\n Results:<\/strong> \r\nLogistic regression analyses showed that the SII score was an important predictor of outcomes in NVAF patients.\r\n
\r\n \r\n \r\n Conclusion:<\/strong> \r\n \r\nThe SII may be a successful, non-invasive, and cost-effective parameter for predicting bleeding and stroke in patients with NVAF. It may be used as a useful risk stratification tool for these patients.\r\n
\r\n \r\n\r\n \r\n <\/div> \r\n <\/div> \r\n \r\n \r\n
\r\n \r\n Keywords:<\/strong> \r\n \r\n systemic immune-inflammation index, atrial fibrillation, direct oral anticoagulants<\/strong> \r\n \r\n <\/div> \r\n \r\n
\r\n \r\n Submitted:<\/strong> June 15, 2025; \r\n Accepted:<\/strong> October 13, 2025; \r\n Published:<\/strong> February 20, 2026
\r\n Cardiovasc J Afr 2025; 37<\/b>: 20-26<\/em>\r\n
Volume 37, Issue 1<\/strong>
\r\n <\/div> \r\n \r\n
\r\n DOI Citation Reference: dx.doi.org\/10.5830\/CVJA-2025-107 \r\n <\/div> \r\n \r\n
\r\n\r\n\r\nUskudar University Faculty of Medicine, Department of Cardiology\r\n<\/strong>
\r\nKahraman Cosansu\r\n\r\n

\r\n\r\nDerince Education and Research Hospital, Department of Cardiology, University of Health Sciences\r\n<\/strong>
\r\nSabiye Yilmaz\r\n\r\n

\r\n\r\nAntalya Education and Research Hospital, Department of Cardiology, University of Health Sciences\r\n<\/strong>
\r\nCagin Mustafa Ureyen\r\n\r\n

\r\n\r\nAnkara Education and Research Hospital, Department of Cardiology, University of Health Sciences\r\n<\/strong>
\r\nMustafa Gokhan Vural\r\n\r\n

\r\n \r\n\r\n [soshsc hide=\"logged\"]\r\n You need to be logged in to view and download<\/a> the full text PDF version. Register for a free account?<\/a><\/strong>

[\/soshsc]\r\n \r\n \r\n \r\n <\/div>\r\n \r\n<\/div>","protected":false},"excerpt":{"rendered":"

The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[44,109],"tags":[],"class_list":["post-5392","post","type-post","status-publish","format-standard","hentry","category-cardiovascular-topics","category-volume-37-issue-1"],"yoast_head":"\nPrognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs - Cardiovascular Journal of Africa<\/title>\n<meta name=\"description\" content=\"The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs - Cardiovascular Journal of Africa\" \/>\n<meta property=\"og:description\" content=\"The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/\" \/>\n<meta property=\"og:site_name\" content=\"Cardiovascular Journal of Africa\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T09:26:56+00:00\" \/>\n<meta name=\"author\" content=\"Jaco Moolman\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jaco Moolman\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/\",\"url\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/\",\"name\":\"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs - Cardiovascular Journal of Africa\",\"isPartOf\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\"},\"datePublished\":\"2026-02-20T09:26:56+00:00\",\"author\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\"},\"description\":\"The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cvja.co.za\/journal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#website\",\"url\":\"https:\/\/cvja.co.za\/journal\/\",\"name\":\"Cardiovascular Journal of Africa\",\"description\":\"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvja.co.za\/journal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920\",\"name\":\"Jaco Moolman\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g\",\"caption\":\"Jaco Moolman\"},\"url\":\"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs - Cardiovascular Journal of Africa","description":"The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/","og_locale":"en_US","og_type":"article","og_title":"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs - Cardiovascular Journal of Africa","og_description":"The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.","og_url":"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/","og_site_name":"Cardiovascular Journal of Africa","article_published_time":"2026-02-20T09:26:56+00:00","author":"Jaco Moolman","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Jaco Moolman","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/","url":"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/","name":"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs - Cardiovascular Journal of Africa","isPartOf":{"@id":"https:\/\/cvja.co.za\/journal\/#website"},"datePublished":"2026-02-20T09:26:56+00:00","author":{"@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920"},"description":"The systemic immune-inflammation index (SII) is a simple parameter that has been used to predict adverse outcomes in different clinical settings. The prognostic value of SII, an innovative biomarker of inflammation, in non-valvular atrial fibrillation (NVAF) patients has not been assessed. The aim of this study was to evaluate the prognostic value of SII in NVAF patients who were under direct oral anticoagulant (DOAC) medication.","breadcrumb":{"@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvja.co.za\/journal\/cvja-2025-107\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cvja.co.za\/journal\/cvja-2025-107\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cvja.co.za\/journal\/"},{"@type":"ListItem","position":2,"name":"Prognostic value of systemic immune-inflammation index in patients with non-valvular atrial fibrillation: SII score in patients using DOACs"}]},{"@type":"WebSite","@id":"https:\/\/cvja.co.za\/journal\/#website","url":"https:\/\/cvja.co.za\/journal\/","name":"Cardiovascular Journal of Africa","description":"The Cardiovascular Journal of Africa is a peer-reviewed medical journal publishing leading research in cardiovascular health across Africa since 1990","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvja.co.za\/journal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/6bf8a30a039e93fd8112db707affb920","name":"Jaco Moolman","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cvja.co.za\/journal\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/454c6719ed785bfd40e036ca3c3ac3347c56b4a99902df8beb62d882b1e6967f?s=96&d=mm&r=g","caption":"Jaco Moolman"},"url":"https:\/\/cvja.co.za\/journal\/author\/jacodesignconnection-co-za\/"}]}},"_links":{"self":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5392","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/comments?post=5392"}],"version-history":[{"count":1,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5392\/revisions"}],"predecessor-version":[{"id":5394,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/posts\/5392\/revisions\/5394"}],"wp:attachment":[{"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/media?parent=5392"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/categories?post=5392"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvja.co.za\/journal\/wp-json\/wp\/v2\/tags?post=5392"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}